The role of primary pharmacological therapy in acromegaly

Pituitary

Volumn 17, Issue SUPPL. 1, 2014, Pages

  Espinosa De Los Monteros, Ana Laura ^a   Carrasco, Carmen A ^b   Albarrán, Alfredo Adolfo Reza ^c   Gadelha, Mônica ^d   Abreu, Alin ^e   Mercado, Moisés ^a,f  

^a HOSPITAL DE ESPECIALIDADES   (Mexico)

^b PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

^c INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

^d FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^e CENTRO MÉDICO IMBANACO   (Colombia)

^f UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

Author keywords

Acromegaly; Dopamine agonists; GH; IGF 1; Latin America; Pegvisomant; Pituitary; Somatostatin analogs

Indexed keywords

CABERGOLINE; GROWTH HORMONE; OCTREOTIDE; PROLACTIN; SOMATOMEDIN C;

ACROMEGALY; ADULT; ARTICLE; CASE REPORT; CLINICAL FEATURE; COST EFFECTIVENESS ANALYSIS; DISEASE CONTROL; DRUG COST; DRUG EFFICACY; GROWTH HORMONE SECRETING ADENOMA; HUMAN; LOW DRUG DOSE; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; SOUTH AND CENTRAL AMERICA; TREATMENT DURATION; TUMOR REGRESSION; TUMOR VOLUME; YOUNG ADULT;

ACROMEGALY; ADENOMA; DOPAMINE AGONISTS; ERGOLINES; HUMAN GROWTH HORMONE; HUMANS; MALE; OCTREOTIDE; PITUITARY NEOPLASMS; SOMATOSTATIN; YOUNG ADULT;

EID: 84898794297     PISSN: 1386341X     EISSN: 15737403     Source Type: Journal    
DOI: 10.1007/s11102-013-0530-0     Document Type: Article

References (54)

1. Melmed S (2009) Acromegaly pathogenesis and treatment. J Clin Invest 119(11):3189-3202
2. Sherlock M, Woods C, Sheppard MC (2011) Medical therapy in acromegaly. Nat Rev Endocrinol 7(5):291-300
3. Barkan A, Bronstein MD, Bruno OD, Cob A, Espinosa-de-los-Monteros AL, Gadelha MR, Garavito G, Guitelman M, Mangupli R, Mercado M, Portocarrero L, Sheppard M (2010) Management of acromegaly in Latin America: expert panel recommendations. Pituitary 13(2):168-175
4. Katznelson L, Atkinson JL, Cook DM, Ezzat SZ, Hamrahian AH, Miller KK; American Association of Clinical Endocrinologists (2011) American Association of clinical endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of acromegaly-2011 update. Endocr Pract 17(Suppl 4):1-44
5. Vallette S, Ezzat S, Chik C, Ur E, Imran SA, Uum S, Rivera J, Caspar-Bell G, Serri O (2012) Emerging trends in the diagnosis and treatment of acromegaly in Canada. Clin Endocrinol (Oxf) 2012 Nov 28. doi:10.1111/cen.12112. [Epub ahead of print]
6. Melmed S, Colao A, Barkan A, Molitch M, Grossman AB, Kleinberg D, Clemmons D, Chanson P, Laws E, Schlechte J, Vance ML, Ho K, Giustina A, Acromegaly Consensus Group (2009) Guidelines for acromegaly management: an update. J Clin Endocrinol Metab 94(5):1509-1517
7. Guinto G, Abdo M, Zepeda E, Aréchiga N, Mercado M (2012) Acromegaly: role of surgery in the therapeutic armamentarium. Int J Endocrinol 2012:306094
8. Katznelson L (2010) Approach to the patient with persistent acromegaly after pituitary surgery. J Clin Endocrinol Metab 95(9):4114-4123
9. Feelders RA, Hofland LJ, van Aken MO, Neggers SJ, Lamberts SW, de Herder WW, van der Lely AJ (2009) Medical therapy of acromegaly: efficacy and safety of somatostatin analogues. Drugs 69(16):2207-2226
10. Giustina A, Bronstein MD, Casanueva FF, Chanson P, Ghigo E, Ho KK, Klibanski A, Lamberts S, Trainer P, Melmed S (2011) Current management practices for acromegaly: an international survey. Pituitary 14(2):125-133
11. Freda PU, Katznelson L, van der Lely AJ, Reyes CM, Zhao S, Rabinowitz D (2005) Long-acting somatostatin analog therapy of acromegaly: a meta-analysis. J Clin Endocrinol Metab 90(8):4465-4473 (Pubitemid 41159328)
12. Mercado M, Borges F, Bouterfa H, Chang TC, Chervin A, Farrall AJ, Patocs A, Petersenn S, Podoba J, Safari M, Wardlaw J, SMS995B2401 Study Group (2007) A prospective, multicentre study to investigate the efficacy, safety and tolerability of octreotide LAR (long-acting repeatable octreotide) in the primary therapy of patients with acromegaly. Clin Endocrinol (Oxf) 66(6):859-868 (Pubitemid 47024274)
13. Cozzi R, Montini M, Attanasio R, Albizzi M, Lasio G, Lodrini S, Doneda P, Cortesi L, Pagani G (2006) Primary treatment of acromegaly with octreotide LAR: a long-term (up to 9 years) prospective study of its efficacy in the control of disease activity and tumor shrinkage. J Clin Endocrinol Metab 91(4):1397-1403
14. Colao A, Auriemma RS, Galdiero M, Lombardi G, Pivonello R (2009) Effects of initial therapy for 5 years with somatostatin analogs for acromegaly on growth hormone and insulin-like growth factor-I levels, tumor shrinkage, and cardiovascular disease: a prospective study. J Clin Endocrinol Metab 94(10):3746-3756
15. Colao A, Auriemma RS, Lombardi G, Pivonello R (2011) Resistance to somatostatin analogs in acromegaly. Endocr Rev 32(2):247-271
16. Gadelha MR, Kasuki L, Korbonits M (2013) Novel pathway for somatostatin analogs in patients with acromegaly. Trends Endocrinol Metab 25(5):238-248
17. Chanson P, Borson-Chazot F, Kuhn JM, Blumberg J, Maisonobe P, Delemer B, Group Lanreotide Acromegaly Study (2008) Control of IGF-I levels with titrated dosing of lanreotide Autogel over 48 weeks in patients with acromegaly. Clin Endocrinol (Oxf) 69(2):299-305 (Pubitemid 352009031)
18. Colao A, Pivonello R, Galderisi M, Cappabianca P, Auriemma RS, Galdiero M, Cavallo LM, Esposito F, Lombardi G (2008) Impact of treating acromegaly first with surgery or somatostatin analogs on cardiomyopathy. J Clin Endocrinol Metab 93(7):2639-2646 (Pubitemid 352008531)
19. Colao A (2012) Improvement of cardiac parameters in patients with acromegaly treated with medical therapies. Pituitary 15(1):50-58
20. Amato G, Mazziotti G, Rotondi M, Iorio S, Doga M, Sorvillo F, Manganella G, Di Salle F, Giustina A, Carella C (2002) Long-term effects of lanreotide SR and octreotide LAR on tumour shrinkage and GH hypersecretion in patients with previously untreated acromegaly. Clin Endocrinol (Oxf) 56(1):65-71 (Pubitemid 34107323)
21. Melmed S, Sternberg R, Cook D, Klibanski A, Chanson P, Bonert V, Vance ML, Rhew D, Kleinberg D, Barkan A (2005) A critical analysis of pituitary tumor shrinkage during primary medical therapy in acromegaly. J Clin Endocrinol Metab 90(7):4405-4410 (Pubitemid 41058228)
22. Giustina A, Mazziotti G, Torri V, Spinello M, Floriani I, Melmed S (2012) Meta-analysis on the effects of octreotide on tumor mass in acromegaly. PLoS ONE 7(5):e36411
23. Fleseriu M (2011) Clinical efficacy and safety results for dose escalation of somatostatin receptor ligands in patients with acromegaly: a literature review. Pituitary 14(2):184-193
24. Ludlam WH, Anthony L (2011) Safety review: dose optimization of somatostatin analogs in patients with acromegaly and neuroendocrine tumors. Adv Ther 28(10):825-841
25. Sherlock M, Fernandez-Rodriguez E, Alonso AA, Reulen RC, Ayuk J, Clayton RN, Holder G, Sheppard MC, Bates A, Stewart PM (2009) Medical therapy in patients with acromegaly: predictors of response and comparison of efficacy of dopamine agonists and somatostatin analogues. J Clin Endocrinol Metab 94(4):1255-1263
26. Sandret L, Maison P, Chanson P (2011) Place of cabergoline in acromegaly: a meta-analysis. J Clin Endocrinol Metab 96(5):1327-1335
27. Schreiber I, Buchfelder M, Droste M, Forssmann K, Mann K, Saller B, Strasburger CJ, German PegvisomantInvestigators (2007) Treatment of acromegaly with the GH receptor antagonist pegvisomant in clinical practice: safety and efficacy evaluation from the German Pegvisomant Observational Study. Eur J Endocrinol 156(1):75-82 (Pubitemid 46553905)
28. Trainer PJ (2009) ACROSTUDY: the first 5 years. Eur J Endocrinol 161(Suppl 1):S19-S24
29. Colao A, Pivonello R, Auriemma RS, De Martino MC, Bidlingmaier M, Briganti F, Tortora F, Burman P, Kourides IA, Strasburger CJ, Lombardi G (2006) Efficacy of 12-month treatment with the GH receptor antagonist pegvisomant in patients with acromegaly resistant to long-term, high-dose somatostatin analog treatment: effect on IGF-I levels, tumor mass, hypertension and glucose tolerance. Eur J Endocrinol 154(3):467-477
30. Feenstra J, de Herder WW, ten Have SM, van den Beld AW, Feelders RA, Janssen JA, van der Lely AJ (2005) Combined therapy with somatostatin analogues and weekly pegvisomant in active acromegaly. Lancet 365(9471):1644-1646 (Pubitemid 40693415)
31. Neggers SJ, van Aken MO, Janssen JA, Feelders RA, de Herder WW, van der Lely AJ (2007) Long-term efficacy and safety of combined treatment of somatostatin analogs and pegvisomant in acromegaly. J Clin Endocrinol Metab 92(12):4598-4601 (Pubitemid 350223432)
32. van der Lely AJ, Bernabeu I, Cap J, Caron P, Colao A, Marek J, Neggers S, Birman P (2011) Coadministration of lanreotide Autogel and pegvisomant normalizes IGF1 levels and is well tolerated in patients with acromegaly partially controlled by somatostatin analogs alone. Eur J Endocrinol 164(3):325-333
33. Barkan AL, Lloyd RV, Chandler WF, Hatfield MK, Gebarski SS, Kelch RP, Beitins IZ (1988) Preoperative treatment of acromegaly with long-acting somatostatin analog SMS 201-995: shrinkage of invasive pituitary macroadenomas and improved surgical remission rate. J Clin Endocrinol Metab 67(5):1040-1048
34. Lucas-Morante T, García-Uría J, Estrada J, Saucedo G, Cabello A, Alcañiz J, BarcelóB (1994) Treatment of invasive growth hormone pituitary adenomas with long-acting somatostatin analog SMS 201-995 before transsphenoidal surgery. J Neurosurg 81(1):10-14 (Pubitemid 24195501)
35. Stevenaert A, Beckers A (1996) Presurgical octreotide: treatment in acromegaly. Metabolism 45(Suppl 1):72-74
36. Colao A, Ferone D, Cappabianca P, Del De Basso Caro ML, Marzullo P, Monticelli A, Alfieri A, Merola B, Calì A, de Divitiis E, Lombardi G (1997) Effect of octreotide pretreatment on surgical outcome in acromegaly. J Clin EndocrinolMetab 82(10):3308-3314 (Pubitemid 27419077)
37. Carlsen SM, Lund-Johansen M, Schreiner T, Aanderud S, Johannesen O, Svartberg J, Cooper JG, Hald JK, Fougner SL, Bollerslev J, Preoperative Octreotide Treatment of Acromegaly Study Group (2008) Preoperative octreotide treatment in newly diagnosed acromegalic patients with macroadenomas increases cures short-term postoperative rates: a prospective, randomized trial. J Clin Endocrinol Metab 93(8):2984-2990
38. Mao ZG, Zhu YH, Tang HL, Wang DY, Zhou J, He DS, Lan H, Luo BN, Wang HJ (2010) Preoperative lanreotide treatment in acromegalic patients with macroadenomas increases short-term postoperative cure rates: a prospective, randomised trial. Eur J Endocrinol 162(4):661-666
39. Biermasz NR, van Dulken H, Roelfsema F (1999) Direct post-operative and follow-up results of transsphenoidal surgery in 19 acromegalic patients pretreated with octreotide compared to those in untreated matched controls. J Clin Endocrinol Metab 84(10):3551-3555 (Pubitemid 30645204)
40. Kristof RA, Stoffel-Wagner B, Klingmüller D, Schramm J (1999) Does octreotide treatment improve the surgical results of macroadenomas in acromegaly? A randomized study. Acta Neurochir (Wien) 141(4):399-405 (Pubitemid 29192189)
41. Abe T, Lüdecke DK (2001) Effects of preoperative octreotide treatment on different subtypes of 90 GH-secreting pituitary adenomas and outcome in one surgical centre. Eur J Endocrinol 145(2):137-145 (Pubitemid 32707599)
42. Plöckinger U, Quabbe HJ (2005) Presurgical octreotide treatment in acromegaly: no improvement of final growth hormone (GH) concentration and pituitary function. A long-term case-control study Acta Neurochir (Wien) 147(5):485-493 (Pubitemid 40603128)
43. Ferone D, Gatto F, Minuto F (2012) Pre-surgical treatment with somatostatin analogues in patients with acromegaly: The case for. J Endocrinol Invest 35(6):613-615
44. Losa M, Crippa VG (2012) Pre-surgical treatment with somatostatin analogues in patients with acromegaly: the case against. J Endocrinol Invest 35(6):616-618
45. Petrossians P, Borges-Martins L, Espinoza C, Daly A, Betea D, Valdes-Socin H, Stevenaert A, Chanson P, Beckers A (2005) Gross total resection or debulking of pituitary adenomas improves hormonal control of acromegaly by somatostatin analogs. Eur J Endocrinol 152(1):61-66 (Pubitemid 40185454)
46. Colao A, Attanasio R, Pivonello R, Cappabianca P, Cavallo LM, Lasio G, Lodrini A, Lombardi G, Cozzi R (2006) Partial surgical removal of growth hormone-secreting pituitary tumors enhances the response to somatostatin analogs in acromegaly. J Clin Endocrinol Metab 91(1):85-92 (Pubitemid 43069122)
47. Jallad RS, Musolino NR, Kodaira S, Cescato VA, Bronstein MD (2007) Does partial surgical tumor removal influence the response to octreotide-LAR in acromegalic patients previously resistant to the somatostatin analogue? Clin Endocrinol (Oxf) 67(2):310-315 (Pubitemid 47076313)
48. Karavitaki N, Turner HE, Adams CB, Cudlip S, Byrne JV, Fazal-Sanderson V, Rowlers S, Trainer PJ, Wass JA (2008) Surgical debulking of pituitary macroadenomas causing acromegaly improves control by lanreotide. Clin Endocrinol (Oxf) 68(6):970-975 (Pubitemid 351703951)
49. Bronstein MD (2010) Optimizing acromegaly treatment. Front Horm Res 38:174-183
50. Vieira Neto L, Abucham J, Araujo LA, Boguszewski CL, Bronstein MD, Czepielewski M, Jallad RS, Musolino NR, Naves LA, Ribeiro-Oliveira A Jr, Vilar L, Faria Mdos S, Gadelha MR (2011) Recommendations of Neuroendocrinology Department from Brazilian Society of Endocrinology and Metabolism for diagnosis and treatment of acromegaly in Brazil. Arq Bras Endocrinol Metabol 55(2):91-105
51. Abrams P, Alexopoulou O, Abs R, Maiter D, Verhelst J (2007) Optimalization and cost management of lanreotide-Autogel therapy in acromegaly. Eur J Endocrinol 157(5):571-577 (Pubitemid 350187373)
52. Gonzalez B, Vargas G, de los Espinosa Monteros AL, Sosa E, Mercado M (2011) Efficacy and safety of radiotherapy in acromegaly. Arch Med Res 42:48-52
53. Attanasio R, Epaminonda P, Motti E (2003) Gamma-knife radiosurgery in acromegaly: a 4 year follow-up study. J Clin Endocrinol Metab 88:3105-3112 (Pubitemid 36877479)
54. Ramirez C, Vargas G, Gonzalez B, Grossman A, Rabago J, Sosa E, De los Espinosa Monteros AL, Mercado M (2012) Discontinuation of octreotide LAR after long term, successful treatment of patients with acromegaly: is it worth trying? Eur J Endocrinol 166:21-26